Using genetic and pharmacological experiments in breast cancer and cardiomyocyte cell lines, we show that STK3 inhibition simultaneously slows breast cancer growth and invasion while providing protection to cardiomyocytes from doxorubicin-induced cardiotoxicity. This evidence concerns the gene STK3 and breast carcinoma.